Does SIMVASTATIN Cause Hepatic lesion? 13 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Hepatic lesion have been filed in association with SIMVASTATIN (Simvastatin). This represents 0.1% of all adverse event reports for SIMVASTATIN.
13
Reports of Hepatic lesion with SIMVASTATIN
0.1%
of all SIMVASTATIN reports
1
Deaths
10
Hospitalizations
How Dangerous Is Hepatic lesion From SIMVASTATIN?
Of the 13 reports, 1 (7.7%) resulted in death, 10 (76.9%) required hospitalization.
Is Hepatic lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SIMVASTATIN. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does SIMVASTATIN Cause?
Myalgia (3,919)
Fatigue (2,066)
Arthralgia (1,775)
Drug interaction (1,744)
Nausea (1,676)
Rhabdomyolysis (1,616)
Dyspnoea (1,542)
Headache (1,470)
Drug hypersensitivity (1,433)
Muscular weakness (1,356)
What Other Drugs Cause Hepatic lesion?
OCTREOTIDE (296)
EVEROLIMUS (171)
RIBOCICLIB (144)
LETROZOLE (139)
CAPECITABINE (124)
ADALIMUMAB (123)
METHOTREXATE (108)
FULVESTRANT (107)
PALBOCICLIB (104)
CYCLOPHOSPHAMIDE (101)
Which SIMVASTATIN Alternatives Have Lower Hepatic lesion Risk?
SIMVASTATIN vs SINGULAIR
SIMVASTATIN vs SINTILIMAB
SIMVASTATIN vs SIPONIMOD
SIMVASTATIN vs SIPULEUCEL-T
SIMVASTATIN vs SIROLIMUS